Medigeshi et al., 2022 - Google Patents
Sub-optimal neutralisation of omicron (B. 1.1. 529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6 …Medigeshi et al., 2022
View HTML- Document ID
- 17493715140885679867
- Author
- Medigeshi G
- Batra G
- Murugesan D
- Thiruvengadam R
- Chattopadhyay S
- Das B
- Gosain M
- Singh J
- Anbalagan A
- Shaman H
- Pargai K
- Mehdi F
- Das S
- Kahlon N
- Singh S
- Kshetrapal P
- Wadhwa N
- Pandey A
- Bhatnagar S
- Garg P
- et al.
- Publication year
- Publication venue
- EBioMedicine
External Links
Snippet
Background Rapid spread of the omicron SARS-CoV-2 variant despite extensive vaccination suggests immune escape. The neutralising ability of different vaccines alone or with natural SARS-CoV-2 infection against omicron is not well-known. Methods In this cross …
- 201000009910 diseases by infectious agent 0 title abstract description 74
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Medigeshi et al. | Sub-optimal neutralisation of omicron (B. 1.1. 529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months | |
| Azzi et al. | Mucosal immune response in BNT162b2 COVID-19 vaccine recipients | |
| Stringhini et al. | Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study | |
| Demonbreun et al. | Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. | |
| Manisty et al. | Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection | |
| Fonseca et al. | Dynamics of antibody response to CoronaVac vaccine | |
| Sasisekharan et al. | Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset | |
| Geanes et al. | Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination | |
| Tuan et al. | Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV | |
| Ascough et al. | Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model | |
| Nguyen et al. | Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial | |
| Guo et al. | Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study | |
| DiazGranados et al. | Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials | |
| Jamiruddin et al. | Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh | |
| Appelman et al. | Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination | |
| Thwaites et al. | Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine | |
| Dobaño et al. | Sustained seropositivity up to 20.5 months after COVID-19 | |
| Breyer et al. | Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown | |
| Nilles et al. | SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection–A multistage national household survey and modelling study, Dominican Republic, June–October 2021 | |
| Gregory et al. | Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19 | |
| Lerdsamran et al. | Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves | |
| Jia et al. | Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses | |
| Frei et al. | Development of hybrid immunity during a period of high incidence of Omicron infections | |
| Mihaylova et al. | Durability of humoral and cell‐mediated immune response after SARS‐CoV‐2 mRNA vaccine administration | |
| Puhach et al. | SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses |